ing the INN due to small differences between an original biologic and that same biologic produced using a slightly different process runs counter to years of naming practice for brand products (a fact that seems to have been conveniently forgotten by innovator companies).
Every now and then, drugmakers of an original biologic make changes to the way they manufacture their product. Such changes can be as trivial as changing their supplier of culture materials or as fundamental as changing the cell line or manufacturing site. When this happens the product may change (a process termed 'drift' in the industry) and regulators require that manufacturers demonstrate that the new product shows physiochemical characteristics, biologic activity and clinical outcomes comparable to those of the original. Importantly, when regulators determine the new product produced by the different process is indeed comparable to the original, the brand manufacturer gets to use the same INN.
The logical inconsistency of arguing for a different INN for a biosimilar (which is deemed by regulators as comparable to an originator product) but keeping the same INN for a brand biologic produced by a different process (which is deemed by regulators as comparable to an originator product) seems to have escaped the Biotechnology Industry Organization (BIO). Responding to the controversy, BIO states that the US Congress should "ensure that follow-on biologics will be assigned a nonproprietary name readily distinguishable from that of the innovator's version. " According to BIO, giving follow-on biologics the same INN as a brand "would be confusing and misleading to patients, physicians and pharmacists, could result in inadvertent substitution of the products, and would make it difficult to quickly trace and address adverse events…. " It is unclear why BIO argues that the INN is important for tracking adverse events when another system-the National Drug Code-is already in use and works independently of the INN.
Fortunately for those who think that 'logical' is a good place for drug regulation to be, the US Food and Drug Administration is not (yet) persuaded of these minority apartheid industry arguments. FDA's 2006 Briefing on Biosimilars says that, INNs should not be used "to differentiate products with the same active ingredient(s)" unless there is credible scientific data either way.
BIO and its brand manufacturer members need to realize they cannot have their cake and eat it, too. If they are demanding modified INNs for biosimilars, then originator products produced using a new process should also be given modified INNs. If such a scenario were adopted, physicians would likely end up having to discombobulate reams of different INNs for brands and biosimilars alike. It is difficult to understand how such a situation would be helpful to prescribing physicians.
What it would mean is doubts sown in minds, impaired competition and ultimately limited patient access to medicines at competitive prices. In the end, the push for a different name really amounts to one thing: let's give biosimilars a bad name.
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